Leerink Partnrs Issues Positive Outlook for NRIX Earnings

Nurix Therapeutics, Inc. (NASDAQ:NRIX) – Investment analysts at Leerink Partnrs lifted their Q2 2025 earnings per share estimates for Nurix Therapeutics in a research note issued on Tuesday, April 8th. Leerink Partnrs analyst F. Khurshid now expects that the company will earn ($0.84) per share for the quarter, up from their prior estimate of ($0.93). Leerink Partnrs has a “Hold” rating on the stock. The consensus estimate for Nurix Therapeutics’ current full-year earnings is ($2.99) per share. Leerink Partnrs also issued estimates for Nurix Therapeutics’ Q3 2025 earnings at ($0.99) EPS, Q4 2025 earnings at ($1.04) EPS, FY2025 earnings at ($3.54) EPS and FY2026 earnings at ($3.37) EPS.

NRIX has been the subject of a number of other research reports. HC Wainwright reaffirmed a “buy” rating and set a $36.00 price objective on shares of Nurix Therapeutics in a research report on Wednesday, April 2nd. Stephens reissued an “overweight” rating and issued a $31.00 target price on shares of Nurix Therapeutics in a research note on Tuesday, January 21st. Needham & Company LLC lowered their price target on Nurix Therapeutics from $28.00 to $27.00 and set a “buy” rating for the company in a research report on Wednesday. JPMorgan Chase & Co. cut their price objective on shares of Nurix Therapeutics from $31.00 to $30.00 and set an “overweight” rating on the stock in a research report on Wednesday, January 29th. Finally, Morgan Stanley lifted their target price on shares of Nurix Therapeutics from $16.00 to $17.00 and gave the stock an “equal weight” rating in a report on Monday, February 3rd. Three analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Nurix Therapeutics has an average rating of “Moderate Buy” and an average target price of $30.44.

Nurix Therapeutics Stock Performance

Shares of NASDAQ NRIX opened at $9.14 on Friday. The company has a 50 day simple moving average of $14.03 and a two-hundred day simple moving average of $19.18. Nurix Therapeutics has a fifty-two week low of $8.18 and a fifty-two week high of $29.56. The company has a market capitalization of $696.80 million, a price-to-earnings ratio of -3.16 and a beta of 2.23.

Nurix Therapeutics (NASDAQ:NRIX) last issued its quarterly earnings results on Tuesday, April 8th. The company reported ($0.67) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.72) by $0.05. Nurix Therapeutics had a negative net margin of 354.85% and a negative return on equity of 53.65%. The company had revenue of $18.45 million during the quarter, compared to analyst estimates of $12.78 million. During the same period last year, the business earned ($0.76) EPS.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. US Bancorp DE lifted its position in shares of Nurix Therapeutics by 144.7% in the fourth quarter. US Bancorp DE now owns 1,424 shares of the company’s stock valued at $27,000 after acquiring an additional 842 shares in the last quarter. GF Fund Management CO. LTD. bought a new stake in Nurix Therapeutics during the 4th quarter valued at approximately $28,000. Aquatic Capital Management LLC purchased a new position in Nurix Therapeutics in the 4th quarter worth approximately $87,000. Summit Investment Advisors Inc. boosted its stake in Nurix Therapeutics by 13.6% in the 4th quarter. Summit Investment Advisors Inc. now owns 7,345 shares of the company’s stock worth $138,000 after purchasing an additional 877 shares during the period. Finally, BNP Paribas Financial Markets bought a new position in Nurix Therapeutics in the 4th quarter worth approximately $164,000.

Insider Buying and Selling

In related news, CFO Houte Hans Van sold 5,825 shares of the stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $14.49, for a total value of $84,404.25. Following the completion of the sale, the chief financial officer now directly owns 33,724 shares of the company’s stock, valued at approximately $488,660.76. This represents a 14.73 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Gwenn Hansen sold 3,690 shares of the firm’s stock in a transaction that occurred on Thursday, January 30th. The stock was sold at an average price of $19.85, for a total transaction of $73,246.50. Following the sale, the insider now owns 55,937 shares in the company, valued at approximately $1,110,349.45. The trade was a 6.19 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 12,326 shares of company stock valued at $213,449. 9.80% of the stock is owned by company insiders.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.